What is HHS's health score?

HARTE HANKS INC (HHS) has a TradeApes health score of 40 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is HHS's estimated fair value?

Based on our 5-year discounted cash flow model, HARTE HANKS INC's estimated fair value is $10.77 per share, representing a 343.2% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is HHS undervalued or overvalued?

Our model currently rates HHS as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

1 free score card remaining

HARTE HANKS INC (HHS)

Technology Undervalued low weak

$2.43

Updated: 2026-07-16

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

40 Weak

Relative Value

15 Stressed

Capital Allocation

55 Mixed

Risk Management

70 Healthy

Est. Fair Value $10.77

DCF Upside +343.2%

Sector Rank #2559 of 15001

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Historically expensive — EV/EBITDA in top 20% of its 5-year range

Unlock Full Report →

Industry Related Stocks

APPLIED OPTOELECTRONICS, INC. (AAOI) AAON, INC. (AAON) Apple Inc. (AAPL) Antiaging Quantum Living Inc. (AAQL) ABB LTD (ABBNY) ABB LTD (ABLZF)

See all Technology stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.